Tranexamic acid is an active site inhibitor of urokinase plasminogen activator
Lysine binding sites (LBSs) of plasminogen (Plg) are essential for maintaining a closed
conformation in circulation and binding to fibrin and cell surface receptors. 1, 2 Upon binding …
conformation in circulation and binding to fibrin and cell surface receptors. 1, 2 Upon binding …
Tranexamic acid is an active site inhibitor of urokinase plasminogen activator
G Wu, BA Mazzitelli, AJ Quek, MJ Veldman… - Blood …, 2019 - research.monash.edu
Lysine binding sites (LBSs) of plasminogen (Plg) are essential for maintaining a closed
conformation in circulation and binding to fibrin and cell surface receptors. 1, 2 Upon binding …
conformation in circulation and binding to fibrin and cell surface receptors. 1, 2 Upon binding …
[引用][C] Tranexamic acid is an active site inhibitor of urokinase plasminogen activator
G Wu, BA Mazzitelli, AJ Quek, MJ Veldman… - Blood …, 2019 - ashpublications.org
Key Points TXA is an active-site inhibitor of uPA. TXA attenuates MDA-MB-231 BAG cell
migration and inhibits endogenous uPA activity.
migration and inhibits endogenous uPA activity.
Tranexamic acid is an active site inhibitor of urokinase plasminogen activator.
G Wu, BA Mazzitelli, AJ Quek, MJ Veldman… - Blood …, 2019 - europepmc.org
Lysine binding sites (LBSs) of plasminogen (Plg) are essential for maintaining a closed
conformation in circulation and binding to fibrin and cell surface receptors. 1, 2 Upon binding …
conformation in circulation and binding to fibrin and cell surface receptors. 1, 2 Upon binding …
[HTML][HTML] Tranexamic acid is an active site inhibitor of urokinase plasminogen activator
G Wu, BA Mazzitelli, AJ Quek, MJ Veldman… - Blood …, 2019 - ncbi.nlm.nih.gov
Lysine binding sites (LBSs) of plasminogen (Plg) are essential for maintaining a closed
conformation in circulation and binding to fibrin and cell surface receptors. 1, 2 Upon binding …
conformation in circulation and binding to fibrin and cell surface receptors. 1, 2 Upon binding …
[PDF][PDF] Tranexamic acid is an active site inhibitor of urokinase plasminogen activator
G Wu, BA Mazzitelli, AJ Quek, MJ Veldman, PJ Conroy… - 2019 - researchgate.net
Lysine binding sites (LBSs) of plasminogen (Plg) are essential for maintaining a closed
conformation in circulation and binding to fibrin and cell surface receptors. 1, 2 Upon binding …
conformation in circulation and binding to fibrin and cell surface receptors. 1, 2 Upon binding …
Tranexamic acid is an active site inhibitor of urokinase plasminogen activator
G Wu, BA Mazzitelli, AJ Quek, MJ Veldman… - Blood …, 2019 - pubmed.ncbi.nlm.nih.gov
Tranexamic acid is an active site inhibitor of urokinase plasminogen activator Tranexamic
acid is an active site inhibitor of urokinase plasminogen activator Blood Adv. 2019 Mar 12;3(5):729-733 …
acid is an active site inhibitor of urokinase plasminogen activator Blood Adv. 2019 Mar 12;3(5):729-733 …
Tranexamic acid is an active site inhibitor of urokinase plasminogen activator.
G Wu, BA Mazzitelli, AJ Quek, MJ Veldman… - Blood …, 2019 - europepmc.org
Lysine binding sites (LBSs) of plasminogen (Plg) are essential for maintaining a closed
conformation in circulation and binding to fibrin and cell surface receptors. 1, 2 Upon binding …
conformation in circulation and binding to fibrin and cell surface receptors. 1, 2 Upon binding …